^
    Back
    Association details:
    Biomarker:CCL2 elevation
    Cancer:Triple Negative Breast Cancer
    Drug:JNK-IN-8 (JNK inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    AACR 2020
    Title:

    Abstract 5067: Suppression of tumorigenicity and metastasis of triple-negative breast cancer (TNBC) by c-Jun N-Terminal Kinase (JNK) inhibitor via reversing immunosuppressive tumor microenvironment (TME)

    Published date:
    06/22/2020
    Excerpt:
    The effect of JNK inhibitor, JNK-IN-8, on TNBC tumor growth and lung metastasis was measured in 4T1.2 syngeneic mouse model....JNK-IN-8 treatment significantly reduced tumor growth...a higher CCL2 level was associated with poor progression-free and overall survival...
    DOI:
    10.1158/1538-7445.AM2020-5067